Abstract
ObjectiveOral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.MethodsWe identified all patients with relapsing-remitting multiple sclerosis treated...
Highlights
Oral immunotherapies have changed the standard of managing relapsing-remitting multiple sclerosis (MS) and prescription practices globally.[1]
While the proportions of patients with no evidence of disease activity were similar in those treated with fingolimod or dimethyl fumarate as their first treatment choice, fingolimod was superior to dimethyl fumarate among patients who switched to oral agents from injectable therapies.[11]
Patients treated with fingolimod tended to have higher Expanded Disability Status Scale (EDSS) and more relapses during the prior year in comparison to those treated with dimethyl fumarate
Summary
Oral immunotherapies have changed the standard of managing relapsing-remitting multiple sclerosis (MS) and prescription practices globally.[1]. Their availability as a first-line treatment has led to their use as a default initial therapy in several countries. The recently published post hoc comparisons combining data from the pivotal placebo-controlled trials[6–9] and observational cohorts[10 11] suggested that fingolimod and dimethyl fumarate are comparable in suppressing episodic inflammatory activity. Results of these studies varied, most probably due to variability in patients’ underlying disease activity. While the proportions of patients with no evidence of disease activity were similar in those treated with fingolimod or dimethyl fumarate as their first treatment choice, fingolimod was superior to dimethyl fumarate among patients who switched to oral agents from injectable therapies.[11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
